Published on 09/12/2025

Diversion Rules: When to Route, Hold, or Scrap

In the evolving landscape of pharmaceutical manufacturing, particularly with the adoption of continuous manufacturing (CM) and process analytical technology (PAT), the need for robust diversion rules is paramount. This comprehensive guide will provide a step-by-step approach to understanding the diversion rules applicable in scenarios such as routing products, holding them for additional assessment, or scrapping them altogether. Emphasis will be placed on regulatory standards including 21 CFR Part 11, EU GMP Annex 15, and guidelines from ICH Q9 on risk management.

Understanding Continuous Manufacturing and Process Analytical Technology

The transition from batch manufacturing to continuous manufacturing is one of the most significant advancements in the pharmaceutical industry. CM enables a more efficient and flexible production process that supports the ongoing demand for high-quality pharmaceuticals. Integrated with process analytical technology, CM not only enhances product quality but also allows for real-time decision-making through real-time release testing (RTRT).

This advancement necessitates the understanding of the definition of key terms and regulatory considerations, which will form the basis for establishing effective diversion rules:

• Continuous Manufacturing: A production process where raw materials are continuously fed into the system and finished products are simultaneously produced.
• Process Analytical Technology (PAT): Systems for designing, analyzing, and controlling manufacturing through timely measurements of critical quality attributes.
• Real-Time Release Testing (RTRT): A regulatory approach that allows for the release of products based on process data instead of end-product testing.

These definitions provide a foundational understanding necessary for developing appropriate diversion rules. Diversion rules ensure compliance with the desired quality through a mechanism that delineates when to route, hold, or scrap production batches based on established criteria and risk assessments.

Regulatory Framework for Diversion Rules

Implementing effective diversion rules requires a thorough understanding of the relevant regulatory frameworks. Regulatory bodies such as the FDA, EMA, and MHRA set forth guidelines that must be adhered to during the manufacturing process.

The FDA process validation guidelines critically underscore the necessity for a robust quality management system that includes validation of all processes, especially in CM environments. Continuous manufacturing systems must prove that they can consistently produce products that meet quality standards. The expectation is to include clear protocols for assessing and applying diversion rules.

According to EU GMP Annex 15, the validation of the manufacturing process, including diversion rules, should be based on risk assessment principles as outlined by ICH Q9. This involves both product-specific and process-specific evaluations to determine the appropriate points of intervention, should deviations or non-conformance occur.

Additionally, compliance with 21 CFR Part 11 is vital, focusing on electronic records and signatures. Any diversion of products or processes must be documented electronically in accordance with these regulations to ensure traceability and compliance during inspections.

Step-by-Step Procedure for Establishing Diversion Rules

Establishing diversion rules involves a systematic approach. Here’s a step-by-step procedure that should be followed:

Step 1: Define theParameters for Diversion

Initially, precise criteria must be established that determine when products should be routed, held, or scrapped. Parameters may include:

• Out-of-specification (OOS) test results.
• Deviation from pre-defined process parameters.
• Failure of real-time release testing outcomes.

Each criterion should be grounded in compliance to both regulatory expectations and internal quality standards. It is critical to involve cross-functional teams, including Quality Assurance, Production, and Regulatory Affairs, in defining these parameters to ensure comprehensive coverage and acceptance.

Step 2: Risk Assessment

Utilizing the principles of ICH Q9 risk management, conduct a thorough risk assessment associated with the processes in question. This will help to identify possible failure modes, their effects, and the likelihood of occurrence. Each potential deviation should be graded based on its impact on product quality, patient safety, and regulatory compliance.

Develop a risk scoring matrix, categorizing each risk into high, medium, or low categories, and establishing a protocol for how to handle deviations depending on this scoring. This metric will guide decisions to either route, hold, or scrap pharmaceuticals in real-time scenarios.

Step 3: Documentation and Standard Operating Procedures (SOPs)

Once the parameters and risks are defined, documenting these in Standard Operating Procedures (SOPs) is essential. SOPs should explicitly detail the conditions under which products are to be routed, held, or scrapped, along with clear responsibilities for personnel involved in decision-making. Documentation must comply with 21 CFR Part 11 standards to maintain electronic documentation integrity and traceability.

Step 4: Training and Implementation

Training personnel on the implemented diversion rules and related SOPs is crucial. All relevant staff, including operators, quality control personnel, and management, should understand the rationale behind the diversion mechanisms and the procedures they need to follow. Regular training sessions and refreshers will help in maintaining a high level of compliance and readiness in response to deviations.

Step 5: Monitoring and Continuous Improvement

The implementation of diversion rules is not static; it requires an ongoing review process. Create a monitoring plan that includes regular assessments of the effectiveness of the diversion rules against actual outcomes. Analyzing data from RMRT (real-time monitoring and release testing) can provide insights into trends and the reliability of risk assessments.

Furthermore, feedback loops should be integrated into the process for continuous improvement. Adjust diversion rules and SOPs based on findings, incorporating lessons learned from any incidents of deviation to enhance robustness.

Common Scenarios for Diversion: Routing, Holding, or Scrapping

Understanding specific scenarios that necessitate diversion can assist in better preparing the organization for managing continuous manufacturing processes effectively. Here are common scenarios along with actionable approaches:

Routing Scenarios

Routing typically refers to directing a product to be processed differently, based on identified deviations that do not critically affect quality. Consider the following examples:

• Investigating a slight deviation in temperature during processing that does not lead to OOS results. Here, rerouting may involve adjusting downstream processing parameters rather than scrapping the batch.
• Detecting a minor inconsistency in raw material specifications that still remains within acceptable limits. In this case, documentation should reflect the investigation and justification for routing the product towards further processing.

Holding Scenarios

Holding products should be considered when deviations present potential quality risks but require further evaluation. Scenarios include:

• When initial testing results indicate OOS but additional tests may confirm quality consistency.
• When there is a need to conduct extensive investigation into a determined trend of anomalies even if the batch remains within acceptable limits.

These cases require maintaining the product in a designated state, with clear documentation on hold status, rationale, expected timeframes for resolution, and communication to relevant departments.

Scrapping Scenarios

Scrapping should be reserved for situations where the product must be discarded due to critical quality failures or non-compliance issues. Here are common instances:

• Results of tests confirming OOS with no chance of recovery through adjustments.
• Known contamination or safety concerns that affect the patient well-being.

Justification for scrapping should be well documented, providing a defensible rationale during audits and inspections.

Conclusion

In the context of continuous manufacturing powered by process analytical technology, establishing and implementing diversion rules is a critical component of ensuring product quality and regulatory compliance. By following this step-by-step tutorial, teams can develop robust diversion strategies that comply with regulatory requirements and safeguard patient safety through precise risk management.

Emphasizing the importance of effective documentation, proper training, and continuous monitoring will not only enhance compliance with regulatory standards but will also contribute to overall process efficiency and product reliability. As the pharmaceutical industry continues to innovate, the proactive management of diversion events will be essential to maintaining the integrity of manufactured products.